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Abstract: Membrane potentials display the cellular status of non-excitable cells and mediate 
communication between excitable cells via action potentials. The use of genetically encoded 
biosensors employing fluorescent proteins allows a non-invasive biocompatible way to read 
out the membrane potential in cardiac myocytes and other cells of the circulation system. 
Although the approaches to design such biosensors date back to the time when the first 
fluorescent-protein based Förster Resonance Energy Transfer (FRET) sensors were 
constructed, it took 15 years before reliable sensors became readily available. Here, we review 
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different developments of genetically encoded membrane potential sensors. Furthermore, it is 
shown how such sensors can be used in pharmacological screening applications as well as in 
circulation related basic biomedical research. Potentials and limitations will be discussed and 
perspectives of possible future developments will be provided. 
Keywords: Genetically Encoded Voltage Indicators (GEVI); membrane potential; 
cardiomyocyte; action potential 
 
1. Measuring Membrane Potentials—Principles and Properties 
The membrane potential, especially the action potential of muscles and nerves, has been measured 
since the middle of the 19th century [1–3], using metal electrodes. The transition to the cellular level 
started in the 1930s [4] with the development of the voltage clamp approach, which was greatly improved 
by the introduction of the patch-clamp technique [5,6]. Patch-clamp is still regarded as the Gold-standard 
for cellular electrophysiology. The big advantage of this approach is that the entire cell can be controlled, 
i.e., clamped to a given potential (voltage-clamp mode) to monitor the membrane current or alternatively 
to a given current (current-clamp mode) to monitor the membrane potential. However, this method bears 
some considerable disadvantages: (i) cells need to be mechanically disturbed by the glass pipette;  
(ii) spatial information is limited to a cell or a patch of membrane without simultaneous recording of  
the potential distribution across the cell membrane; and (iii) moving cells, like cardiomyocytes within 
an intact beating heart can not be characterized. All these limitations can be overcome by using  
contact-free optical read-outs. All optical sensors for investigations of the membrane potential developed 
so far, independent of whether they rely on small molecule dyes or genetically encoded chromophores, 
are based—directly or indirectly—on membrane potential-induced changes of fluorescent properties. 
Fluorescence read-out has general advantages over absorption detection [7]. Nevertheless, for a high 
spatial and temporal resolution (≤1 ms) maintained over a recording duration of minutes, the number of 
emitted photons becomes the limiting factor. An alternative is non-fluorescent optical recordings, as it 
was shown for dark field microscopy based on abnormal dispersion [8]. This study depicted that the dark 
field optical signal was linear proportional to the change in membrane potential. 
Small molecule dyes have a number of advantageous properties, but suffer from the unspecific 
staining of all cell types. A possible alternative is genetic targeting using tissue specific promotors.  
In addition to the fluorescent protein based voltage sensors (see below), it is worthwhile to mention the 
combination of genetic targeting and conventional organic chromophores [9]. In a proof of principle 
report, it was described that a membrane targeted phosphatase was able to cleave the hydrophilic 
phosphate group of a precursor dye, leading to a membrane bound voltage sensitive dye [10]. A further 
hybrid approach utilized the expression of a membrane bound GFP as Förster Resonance Energy 
Transfer (FRET) donor in combination with dipicrylamine (DPA), a synthetic voltage sensing molecule, 
as FRET acceptor [11]. This hybrid approach has the advantage of genetic targeting but suffers from the 
common disadvantages of small molecule dyes such as the limitations for long-term observation. There 
are controversial reports about the usability of this construct. While DiFranco and colleagues applied it 
successfully in the transverse tubules in mouse skeletal muscle fibers [12] and recently Ghitani et al. [13] 
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reported imaging of spikes and synaptic potentials in single neurons, Sjulson and Miesenböck showed 
that—due to DPA-induced increase in membrane capacitance—it was not possible to detect action 
potentials in the Drosophila antennal lobe [14]. 
Optical membrane potential sensors, whether small molecules, genetically encoded, or combinations 
thereof, share the property of reporting primarily membrane potential changes and not an absolute 
voltage. Ratiometric sensors allow in principle a calibration to absolute voltage, but obstacles like 
different bleaching of donor and acceptor in FRET based sensors render such procedures difficult. 
Another approach is to consider time domain based changes of photopysical properties like fluorescence 
lifetime imaging. In line with such considerations, a special microbial rhodopsin was engineered, where 
the temporal dynamics of the fluorescence was read out in pump-probe experiments reaching a voltage 
accuracy of 10 mV [15]. Although a quantitative calibration for particular indicators is possible, it has 
technical challenges and is therefore rarely used. 
2. Approaches of Genetically Encoded Voltage Indicators 
Genetically encoded membrane potential sensors, fluorescent protein based voltage sensors or 
optogenetic voltage reporters are different synonyms for the same kind of membrane potential probes 
that are termed GEVIs (Genetically Encoded Voltage Indicators) throughout this review. Beside all 
varieties throughout the genesis of GEVIs, they all share voltage sensing domains that are based on  
(or part of) an integral membrane protein, which makes GEVIs a nice example for the Special Issue 
“Membrane Protein Based Biosensors”. 
2.1. GEVI (Genetically Encoded Voltage Indicators) Based on Voltage Sensitive  
Conformational Changes 
The first voltage sensors solely comprising genetically encoded proteins (called FlaSh) comprised a 
wtGFP fused to the C-terminus of the Drosophila Shaker K+-channel [16]. Later, FlaSh was improved 
for kinetics and voltage range [17]. The second GEVI generated independently was based on the fourth 
transmembrane segment (S4) of the voltage gated K+ channel Kv2.1 coupled to a CFP/YFP FRET pair 
in sequence and was named VSFP1 [18]. This sensor was followed by a circular permutated version of 
the fluorescent protein [19]. The third GEVI type was called SPARC and comprised a GFP fused between 
domains I and II of the rat skeletal muscle Na+ channel [20]. These three GEVIs lack distinct membrane 
localization [21]. In addition, they all displayed only modest fluorescence changes (0.5%–5%) for a 
membrane potential change of 100 mV [16,18,20]. The combination of both properties made them fail 
in biological applications. A new generation of GEVIs comprised self-contained voltage sensor domains, 
such as the voltage sensing domain of the Ciona intestinalis Voltage Sensor-containing Phosphatase  
(Ci-VSP) [22], or voltage sensor domain only proteins [23]. 
The Ci-VSP domain was chosen by two groups of the same institution (Brain Science Institute, 
RIKEN, Japan) that independently developed what is now termed VSFP2.x [24] and Mermaid [25]. 
Based on the VSFP2.1 design, further developments were undertaken. Linker optimization led to 
VSFP2.3. In a study using spectrally resolved data VSFP2.3 and Mermaid displayed similar ratio 
changes of around 13% per 100 mV potential change under seemingly similar conditions [26]. Based on 
VSFP2.3 linked to a pair of fluorescent proteins improved for FRET (Clover and mRuby2),  
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an enhanced sensor termed VSFP-CR was introduced (Figure 1) [27]. Selected basic biophysical 
properties of the most popular of these and the following described GEVIs with an emphasis on 
circulation research are summarized in Table 1. 
 
Figure 1. Voltage-Sensitive Fluorescent Protein Clover-mRuby2 (VSFP-CR) for 
phenotyping stem cell derived cardiomyocytes. (A) Overview of optically recorded  
(Di-8-ANEPPS) reference action potential phenotypes from induced pluripotent stem cell 
derived cardiomyocytes. This panel is reproduced from [28], with permission from John 
Wiley & Sons; (B) Recorded image series of a human stem cell derived cardiomyocyte 
expressing VSFP-CR (Lentiviral gene transfer). The images are snapshots every 100 ms of 
a time series recorded at 500 frames per second using a scientific Complementary  
Metal-Oxide-Semiconductor (sCMOS) camera and point to the time course of the recorded 
action potential. Considering the temporal response of the GEVI (Genetically Encoded 
Voltage Indicators), the example shows most alikeness with an “intermediate” action 
potential with a tendency to the ventricular phenotype. Overlay of the raw ratio trace (black) 
and a smoothed trace (blue); (C) Original and processed traces of a train of recorded action 
potentials of an electrically paced (1 Hz) stem cell derived cardiomyocyte. (a) Raw traces of 
the spectral channels for Clover and mRuby2; (b) Overlay of the raw ratio trace (black) and a 





























Int. J. Mol. Sci. 2015, 16 21630 
 









Principle Design and 
Operation with 
Permission from  
Elsevier [29] 
∆R/R per  
100 mV (1–3)  




Temporal Response (on); 
Jump from –70 mV to  
at least +30 mV 
Application in  
Circulation 
Research/Comments 












13.3% ± 3.4% [26], 
10% ± 1% [27] 
half activation 
~–40 mV [27] 
biexponential  
2.5 ± 0.5 and 25 ± 3 ms  
−70 to +60 mV and  
35 °C [26] 
optical mapping in 
transgenic mouse heart [31] 







12.9 ± 4.8% [26] 
half activation 
~–40 mV [25] 
biexponential  
2.5 ± 0.5 ms (23% ± 5%) 
and 25 ± 3 ms at 35 °C [26] 
cardiotoxicity screens in 
vivo (zebrafish) [32] and in 
isolated cardiac myocytes 
(rat) [33]; optical mapping 





13 ± 1% [27] 
half activation 
~–40 mV [27] 
biexponential  
5.4 ± 0.8 and 59.5 ± 5.5 ms 
at 20 °C [27] 
measurements in stem cell 
derived cardiomyocytes for 
phenotyping (this paper)  







~–25 mV [34] 
biexponential ~17.4 ms 
(~39%) and ~123 ms at  
23 °C [36] 
stem cell derived 
cardiomyocyte  
phenotyping [37] 
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Principle Design and 
Operation with 
Permission from  
Elsevier [29]
∆R/R per  
100 mV(1–3)  
∆F/F per  
100 mV (4–8) 
Detection  
Range 
Temporal Response (on); 
Jump from −70 mV to  




5 ASAP1 [38] 
chicken  






–120 to −50 mV 
superlinear and  
–50 to 50 mV 
linear  
response [38] 
biexponential 2.1 ± 0.2 ms 
(60.2%± 1.2%) and  
71.5 ± 1.6 ms [38] 








rhodopsin 3 [40] 
~40% [36] 
–150 to +150 mV 
almost linear 
response [40] 
biexponential < 0.5 ms 
(~20%) and ~41 ms [40] 
mapping of membrane 
potential in transgenic 
zebrafish heart [41]   
7 QuasAr2 [36] 
modified Archae-
rhodopsin 3 [36] 
90% ± 2% [36] 
–100 to +50 mV 
almost linear 
response [36] 
biexponential 1.2 ± 0.1 ms 
(68%) and 11.8 ± 1.5 ms; 
similar on rising and 
falling edge [36] 
t.b.d./most bathochromic 
GEVI (exitation  
590 nm, emission  
715 nm); although high 
sensitivity, fluorescence 
intensity is ∼50-fold 
dimer than GFP [39] 
8 MacQ [42] 
voltage induced shifts in the 
absorption spectrum of 
Leptosphaeria maculans rhodopsin 
results in quenching of the attached 
mCitrine or mOrange2 [42], 
although FRET is happening,  
only the intensity change of the 
donor is measured 
~20% [42] 
–100 to 0 mV 
almost linear 
response, leveling 
out at 0 mV [42] 
biexponential 2.8 ± 0.2 ms 
(74% ± 2%) and 71 ± 3 
ms (26% ± 2%) for 
mCitrine and 2.9 ± 0.1 ms 
(96% ± 1%) and 115 ± 10 
ms (4% ± 1%) for 
mOrange2 [42] 
t.b.d./based on the  
same principle a palette 
of multicolored  
GEVI have been 
introduced [39] 
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A further line of development explored alterations in the fluorescent entities: circular permutated 
fluorescent proteins [43] and red-shifted variants [44] with positive proof of principles but moderate 
intensity changes were generated. Another approach, in contrast to previous designs, was to sandwich 
the voltage sensing domain (of VSFP2.x) between the two fluorescent proteins resulting in VSFP 
“Butterfly” [45]. Using the two fluorescent proteins mCitrine and mKate yielded a membrane probe that 
allowed imaging of electrical responses of the somatosensory cortex in head fixed mice as a proof of 
principle in vivo [45]. 
All GEVIs so far share the property of a fast and a slow kinetic response component. While the fast 
component results from sensing currents within the voltage sensing domain, the slow component is a 
consequence of the voltage-dependent conformational change in the probe [46]. The Knöpfel group 
performed seminal work in linker and fluorescent read-out optimization and introduced a novel probe 
named VSFP3.1 [30]. This construct was characterized by a dramatic shift of the slow sensing 
component towards faster read-out kinetics. This approach based on a response of the voltage sensing 
domain in the absence of major conformational changes of the fluorescence components and thus no 
changes in intramolecular FRET. These properties resulted in intensity changes of approximately 0.5% 
per 100 mV potential change [30]. When considering the overall properties of VSFP3.1, it appears  
to be of restricted use. Similar to this, other approaches employing voltage sensing domains of  
voltage-gated phosphatases of other species, in particular starlet sea anemone (Nematostella vectensis) 
and zebrafish (Danio rerio), also resulted in sensors with a fast kinetic response (2–5 ms) but with rather 
small intensity changes (0.3% per 100 mV voltage change) [47]. 
Based on Mermaid, an improved GEVI was designed using a similar rational as for the VSFP3.x  
probes [34] but taking super ecliptic pHluorin [35] as the fluorescent protein. This sensor was named ArcLight 
and displayed a large fluorescence response of more than 30% per 100 mV voltage change [34,36]. For 
ArcLight, a replacement of the voltage sensing domain from that of the sea squirt to the one from chicken 
(Gallus gallus) and zebrafish (Danio rerio) was reported to improve the temporal response, but at the 
expense of the response amplitude [48]. 
According to an initial report, the Accelerated Sensor of Action Potentials (ASAP1) is currently the 
best non-ratiometric GEVI in this group of voltage sensitive fluorescent proteins [38]. It is based on the 
voltage-sensitive phosphatase of chicken (Gallus gallus) and displays around 29% fluorescence change per 
100 mV voltage change [39]. In addition, the kinetic was also advantageous, the activation response of the 
fast component of 2.1 ± 0.2 ms represented approximately 60% of the total signal amplitude (Table 1) [38]. 
2.2. Microbial Opsin-Based GEVIs 
A completely different concept for GEVI design is based on the use of microbial opsins [49] and 
resulted in the development of sensors named PROBS and Arch [40,49]. The latter one is derived from 
the rhodopsin protein, Archaerhodopsin 3 [40]. Microbial opsins bind retinal, a vitamin A-related 
organic chromophore, and have evolved naturally to function as transducers of light into cellular signals. 
These proteins are known as tools for optogenetic manipulation [50]. The natural occurring relationship 
between light and voltage can be reversed, so that membrane voltage changes are reported as an optical 
signal. In the initial construct of Arch, the light required for imaging activated a proton current resulting in a 
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contra productive change of the membrane potential. Although a point mutation (D95N) abolished Archs’ 
capacity to elicit light-driven currents, it also impaired the temporal response [40]. 
The microbial opsin-based GEVIs were improved ever since leading to new versions of Arch, like  
Arch-EEN and Arch-EES [51], Archer1 and Archer2 [52] and the QuasAr’s (QuasAr1 and QuasAr2) [36]. 
QuasAr2 displays a substantial change in fluorescence per 100 mV change of membrane potential  
of approximately 90% and an activation response of the fast component of 1.2 ± 0.1 ms that reflects 
approximately 68% of the response (Table 1) [36]. Although QuasAr2 has a high dynamic response,  
its overall fluorescence intensity is 30- to 80-fold dimmer than GFP [39]. 
The combination of fluorescent proteins with a fungal rhodopsin (Leptosphaeria maculans) to 
perform FRET resulted in the development of MacQ-GEVIs with a good responsiveness of around  
20% per 100 mV of voltage change and an activation response of the fast component of 2.2 ± 0.2 ms 
representing approximately 74% of the total signal (Table 1) [42]. A very similar strategy was performed 
combining QuasAr2 with various fluorescent proteins from eGFP to mKate2 [39]. 
2.3. Sensing Non-Linear Optical Properties of Fluorescent Proteins 
All previously described approaches using genetically encoded voltage sensors are based on native 
voltage sensing proteins that functionally rely on protonation or conformational changes, such as voltage 
dependent protonation of the retinal Schiff base or voltage dependent phosphatases. Their mechanical 
action towards conformational changes in the sensing domains induce steric alterations in the fluorescent 
proteins that are utilized to provoke and subsequently measure changes in fluorescence intensity. A 
different approach would be to explore possible interactions between the membrane potential and the 
chromophore itself. The Stark effect caused by electric field changes is used in small molecular  
dye-based voltage sensors, e.g., [53]. However, for chromophores of fluorescent proteins this effect is 
too small to be detected by fluorescence microscopy. This highlights other properties of chromophores 
that have hardly been appreciated in the development of biosensors in general. These are the non-linear 
properties allowing the employment of second harmonic generation (SHG) in response to femtosecond 
pulsed infrared light. The general concept [54,55] and initial attempts [55,56] are summarized in [57] 
but they were not explored further. 
3. Examples of GEVIs in Circulation Research 
With the development of the sCMOS technology camera acquisition rates in combination with high 
quantum efficiencies (up to 0.7 for front illuminated sensors) have reached a level that allowed the transition 
from photometric measurements of individual cells to area detectors [58]. The latter detectors enable the 
simultaneous recording of cell populations in combination with good subcellular resolution [59]. Although 
GEVIs seem to be much more popular in neurosciences compared to circulation research [60], we identified 
three major heart related applications, which are detailed below. In addition to cardiac myocytes, other 
(non-excitable) cells of the circulation show membrane potential changes, like T-cells when activated [61], 
red blood cells under volume regulation [62] or endothelial cells of vessels under inflammation [63]. 
However, these rather moderate changes in membrane potential were not compatible with rather limited 
intensity changes of many of the GEVIs. However, latest developments [36,38,39,42] may enable further 
applications in the above-mentioned examples. 
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3.1. Cardiotoxicity Screens 
Conceptual studies of cardiotoxicity screens based on GEVI have been performed with “Mermaid”, 
a sensor introduced in 2008 [25]. Mermaid displayed relative ratio changes around 13% per 100 mV 
membrane change (measured between the membrane potentials of −80 and +20 mV) [25] and therefore 
compares well with small molecule dyes such as RH-237 or di-8-ANEPPS [64]. We even noticed  
a 25% higher change of the relative fluorescence ratio compared to the ratiometric read-out mode of  
di-8-ANEPPS [65]. We have to note that these values refer to a simple ratio of the two spectral channels 
allocated to the FRET donor and acceptor. Calculation of the real FRET efficiency or the apparent FRET 
efficiency [66] has not been achieved yet, because alternating dual excitation has not yet met the necessary 
temporal resolution. However, in adult cardiomyocytes, pharmaceutical prolongation of the action potential 
could be detected readily [33]. This prolongation of the action potential duration can be regarded as a cellular 
equivalent of the QT-interval prolongation in the ECG, which is a pro-arrythmogenic indicator [67]. Thus, 
optical measurements of action potentials in cardiomyocytes expressing a GEVI allow for pharmacological 
safety screens, as shown in pilot studies [33,65]. 
Furthermore, a transgenic zebrafish (Danio rerio) expressing Mermaid under the control of a cardiac 
specific promotor [32] demonstrated the first in vivo imaging of voltage dynamics in a whole heart. 
Although this study is eminent for having the first optical in vivo potential recordings of the entire heart, 
transfer from zebra fish cardiac physiology to relevant tasks of mammalian and human circulation 
research is rather equivocal. 
3.2. Stem Cell Derived Cardiomyocyte Phenotyping 
Differentiating cardiomyocytes from embryonic or induced pluripotent stem cells (iPS-cells) is 
becoming increasingly popular with a wide variety of applications [68,69]. However, the stem cell 
derived cardiomyocytes contain a mixture of different phenotypes, like ventricular myocytes, atrial 
myocytes or myocytes of the conduction system. For the experimental design as well as for further 
differentiation, it is desirable to purify or just identify a particular subtype of cardiomyocytes.  
All subtypes have a different gene expression, but are morphologically indistinguishable. A method to 
discriminate the cell type is the shape of their action potential, which is characteristic for the subtypes 
mentioned above [28]. An elegant way to measure such an action potential is by means of a GEVI,  
as shown for ArcLight expressed in cardiomyocytes from human embryonic stem cells [37]. 
Although ArcLight, which was introduced in 2012 [34], is not a ratiometric GEVI, it could resemble 
the action potential shape and thus allow for a phenotyping of the stem cell derived cardiomyocytes [37]. 
Further advancements might be possible with the introduction of novel ratiometric GEVIs like  
VSFP-CR that allows lentivirus-mediated expression in induced pluripotent stem cell derived cardiac 
myocytes, as seen in Figure 1. 
3.3. Optical Mapping in Transgenic Heart 
Mapping of action potentials in excised hearts is a popular method for exploring pathophysiological 
processes preferentially in animal models. Electrode arrays have been used for such purpose, but they 
have a limited spatial resolution [70]. An alternative is optical mapping that was so far performed with 
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small molecule dyes [71,72]. Considering all the disadvantages of the small molecule dyes such as cell 
toxicity, cell unspecific loading, cell internalization, etc. it would be advantageous to perform these 
measurements with tissue-specific targeted GEVIs. This would enable researchers to perform in situ 
recordings, as done for genetically encoded calcium sensors [73]. 
The first optical mapping of the heart with GEVIs in vivo was reported for zebrafish using 
Arch(D95N) as part of a dual function calcium and voltage reporter (CaViar) [41]. In this paper, optical 
mapping of action potentials and calcium transients in combination with pharmacological probing 
documented the chamber specific developmental transition in ionic currents [41]. 
Recently, a report based on a transgenic mice line expressing VSFP2.3 introduced the methodology to 
mammals [31]. As depicted in Figure 2, these published results are in agreement with our own observations 
based on a transgenic mouse expressing Mermaid. Both approaches show a homogenous expression in the 
heart (Figure 2A), the right subcellular localization at the plasma membrane (Figure 2B), normal 
development and function of the heart (Figure 2C), undisturbed action potentials in agreement with  
patch-clamp (Figure 2D) and an optical read out of the cardiac action potential (Figure 2E). However, a 
limitation is the minute signal change (max. 0.25%, Figure 2E). It is worthwhile to highlight that the 
examples shown in Figure 2 provide a first proof that optical mapping based on GEVIs is possible in 
mammalian hearts, but routine measurements to investigate putative differences under different 
experimental conditions requires improved sensors and experimental settings. 
4. Summary and Perspective 
The development of GEVIs is not yet as mature as genetically encoded calcium indicators  
(GECIs) [74]. Both sensor types are related to one another in circulation research trough the process of 
excitation-contraction coupling [75]. However, GEVI design and characterization has gained large 
momentum in recent years resulting in an exponential increase in the numbers of publications. The major 
improvements of the sensors are accompanied by an increasing number of scientists recognizing the 
tremendous potential of such genetically encoded probes. Thus, recent papers on GEVIs started 
broadening focus from the engineering, characterization and proof of principle to reports of their 
application in physiology or pathophysiology-driven studies [37,76]. 
Although the development of the GEVIs was initially led by applications in neuroscience [29],  
the examples presented here on cardiac cells and cardiac tissues pave the way for an application in 
circulation research as well as in the pharmaceutical industry, especially for cardiac safety screens.  
We face the situation of a delay between the introduction of a GEVIs and their application, because of 
intermediate steps, including the generation of transgenic animals or viruses for gene transfer [77]  
and the establishment of a reproducible and robust read-out mode. In this context, we can expect that 
recently introduced GEVIs (see lower part of Table 1) and novel sensors to be developed will replace 
the GEVIs so far used in circulation research. 





Figure 2. Transgenic mice expressing a Genetically Encoded Voltage Indicator (GEVI) for 
optical mapping of the heart. Comparison of mice expressing VSFP2.3 (left, all panels (a)) 
and Mermaid (right, all panels (b)). Although slightly different parameters are presented, 
both mice show consistent data. (A) Cardiac appearance of the GEVI expression. (a) View 
of the excised heart; (b) Cut open heart: left, short axis; right, long axis; (B) Isolated cells 
expressing the GEVI on the plasmalemma, including T-tubules. (a) Confocal section; (b) 3D 
reconstruction based on confocal recordings; (C) GEVIs neither alter morphologic nor 
functional cardiac parameters. (a) Echocardiographic based parameters of different VSFP2.3 
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mouse lines compared to WT and GCaMP2 mice [73]: top left, heart weight to body weight 
ratio (HW/BW); top right, fractional area shortening (FAS); bottom left, diastolic left 
ventricular inner diameter (LVIDd); bottom right, systolic left ventricular inner diameter 
(LVIDs). None of the mice lines showed any significant differences except for the comparison 
with GCaMP2 mice (n = 8 mice per genotype); (b) Magnetic resonance imaging based 
parameters of Mermaid mice compared to WT: top left, left ventricular mass (LVM); top 
middle, left ventricular stroke volume (LVSV); top right, left ventricular ejection fraction 
(LVEF); bottom left, heart rate; bottom middle, right ventricular ejection fraction (RVEF). 
None of the parameters showed significant differences between Mermaid and WT mice  
(n = 6 mice per genotype); (D) Patch-clamp related measurements in mice expressing GEVI. 
(a) Left: representative traces of CFP and YFP in response to a voltage step from −70 to  
+50 mV in cardiomyocytes expressing VSFP2.3. Right: YFP/CFP ratios in response to a 
voltage protocol as depicted in cardiomyocytes expressing VSFP2.3, the optical signals show 
a pronounced delay compared to the command voltage as was also shown for Mermaid in 
cardiomyocytes [33]; (b) Action potential (AP) properties of Mermaid mice compared to WT 
at a stimulation frequency of 5 Hz: left, AP amplitude; right, AP duration (APD) for 30% and 
70% repolarization. None of the parameters showed significant differences between Mermaid 
and WT mice (n = 10 cells per genotype); (E) Proof-of-principle for Langendorff-perfused 
heart recordings of mice expressing GEVI. (a) Synchronous electrical cardiograms (ECG) and 
optical cardiograms (OCG) supplemented with representative images during 10 Hz electrical 
pacing via a point electrode; (b) Synchronous ECG and raw fluorescence traces (based on the 
region of interest as indicated by the red rectangle in the relative fluorescence (rel. fl.) image) 
of an autonomous beating heart (top traces) were subjected to a Fast Fourier Transformation 
(FFT, left graph). The FFT phase at the frequency of interest (beating frequency of the heart) 
was visualized for each pixel (bottom right) to map the temporal AP distribution over the heart. 
Items in the left column (all panels (a)) are reproduced from [31], with permission from 
Wolters Kluwer. 
Future sensors will further drive forward the unifying advantageous properties of single GEVIs. This 
will enable superior properties of GEVIs, such as a combination of high fluorescence intensity and high 
dynamic range, which will allow applications in non-excitable cells. Red or far-red GEVIs will allow 
measurements combining several sensors, e.g., phosphorylation probes [78] in combination with GEVIs, 
or probing red blood cells, where quantitative biosensors need to be outside the absorption spectrum of 
hemoglobin [79]. The combination of high intensity, high dynamic range and high temporal response 
will facilitate investigations of sub-cellular components of action potentials as already performed for 
calcium transients and thus reveal inhomogeneous generation of voltage signals or inhomogeneous 
distribution and propagation of voltage changes that might contribute to, e.g., cardiac alternans or other 
forms of arrhythmias in the heart [80]. 
With these improvements, the general applicability of GEVIs will rise and render it a powerful 
extension of traditional electrophysiology. The latest progress in both GEVI development and imaging 
technology may bring optogenetic readouts more in line with classical current-clamp measurements and 
may for particular applications such as those described above even outperform them. This may especially 
Int. J. Mol. Sci. 2015, 16 21638 
 
 
hold true in combination with optogenetic induction of action potentials using channelrhodopsin or 
related proteins [36]. 
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